Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Charles Gore

Chief executive, The Hepatitis C Trust

Recent stories

  • Why are hepatitis C patients treated differently by NHS England?Subscription

    8 AUG 2016

    NHS England’s decision to cap access to National Institute for Health and Care Excellence (NICE) approved hepatitis C treatments has been attributed to their cost. These antiviral medicines have led to vast costs for national healthcare systems and huge profits for the pharmaceutical industry. So it is understandable that the mainstream media and general public assume that the cost to the NHS (either per patient or in absolute terms) is prohibitive. In the absence of any other guide, t

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.